Cover Image
市場調查報告書

溶血磷脂酸受體1:開發平台分析

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 359823
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
溶血磷脂酸受體1:開發平台分析 Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 37 Pages
簡介

本報告提供以溶血磷脂酸受體1為標的的藥物適應症,開發階段,作用機制,給藥途徑及各分子類型分析,藥物的藥理作用之相關記述,並彙整迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

溶血磷脂酸受體1概要

治療藥的開發

溶血磷脂酸受體1:開發中的產品 - 各開發階段

溶血磷脂酸受體1:開發中的產品 - 治療範圍別

溶血磷脂酸受體1:開發中的產品 - 各適應症

溶血磷脂酸受體1:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

溶血磷脂酸受體1:企業開發中的產品

溶血磷脂酸受體1:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

溶血磷脂酸受體1治療藥的開發企業

  • AdAlta Pty Ltd.
  • Bristol-Myers Squibb Company
  • Epigen Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ono Pharmaceutical Co., Ltd.
  • RxBio, Inc.
  • Sanofi

藥物簡介

溶血磷脂酸受體1:暫停中的計劃

溶血磷脂酸受體1:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1094TDB

Summary:

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion.

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3 and 3 respectively. Report covers products from therapy areas Respiratory, Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Oncology, Toxicology and Undisclosed which include indications Pulmonary Fibrosis, Diabetic Neuropathy, Diarrhea, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Metastatic Breast Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Systemic Sclerosis (Scleroderma) and Unspecified.

The latest report Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
  • The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Overview
    • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Companies Involved in Therapeutics Development
    • Bristol-Myers Squibb Co
    • Epigen Biosciences Inc
    • F. Hoffmann-La Roche Ltd
    • Ono Pharmaceutical Co Ltd
    • RxBio Inc
    • Sanofi
    • Ube Industries Ltd
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Drug Profiles
    • BMS-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rx-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-100842 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Lysophosphatidic Acid Receptor 1 for Unspecified Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UD-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Dormant Products
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation
      • May 11, 2011: Amira To Present Preclinical Data On AM152 At Annual Meeting Of American Thoracic Society
      • May 02, 2011: Amira Pharmaceuticals Completes Phase I Clinical Study Of AM152
      • Apr 19, 2011: Amira Receives Orphan Drug Status For AM152 In Idiopathic Pulmonary Fibrosis
      • Oct 28, 2010: Amira Initiates Phase I Clinical Trial For AM152
      • Sep 27, 2010: Amira Submits AM152 IND To FDA For Potential Use In Fibrotic Diseases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Pipeline by Epigen Biosciences Inc, H2 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
  • Pipeline by RxBio Inc, H2 2017
  • Pipeline by Sanofi, H2 2017
  • Pipeline by Ube Industries Ltd, H2 2017
  • Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top